Loading clinical trials...
Loading clinical trials...
A Follow-up Study to Assess the Evolution and Persistence of Resistance to ABT-333 After Discontinuation of ABT-333 Therapy in HCV Genotype-1 Infected Subjects Who Participated in Phase 1, 2, or 3 ABT-333 Clinical Studies
Conditions
Interventions
Blood sample collection only
ABT-333
Locations
7
United States
Site Reference ID/Investigator# 17665
Anaheim, California, United States
Site Reference ID/Investigator# 17367
Los Angeles, California, United States
Site Reference ID/Investigator# 17672
Los Angeles, California, United States
Site Reference ID/Investigator# 10381
Orlando, Florida, United States
Site Reference ID/Investigator# 17667
Baton Rouge, Louisiana, United States
Site Reference ID/Investigator# 14461
San Antonio, Texas, United States
Start Date
August 1, 2008
Primary Completion Date
May 1, 2010
Completion Date
May 1, 2010
Last Updated
January 8, 2015
NCT06928259
NCT05992077
NCT05534633
NCT07412977
NCT07241962
NCT04134767
Lead Sponsor
AbbVie (prior sponsor, Abbott)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions